204 related articles for article (PubMed ID: 33496742)
21. [Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome].
Aĭsina RB; Mukhametova LI; Ostriakova EV; Seredavkina NV; Patrushev LI; Patrusheva NL; Reshetniak TM; Gulin DA; Gershkovich KB; Nasonov EL; Varfolomeev SD
Biomed Khim; 2014; 60(1):72-93. PubMed ID: 24749249
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen activator inhibitor-1 levels and polymorphisms.
Francis CW
Arch Pathol Lab Med; 2002 Nov; 126(11):1401-4. PubMed ID: 12421149
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.
Inoue M; Sawada T; Uchima Y; Kimura K; Nishihara T; Tanaka H; Yashiro M; Yamada N; Ohira M; Hirakawa K
Oncol Rep; 2005 Dec; 14(6):1445-51. PubMed ID: 16273237
[TBL] [Abstract][Full Text] [Related]
24. Genetic association between plasminogen activator inhibitor-1 rs1799889 polymorphism and venous thromboembolism: Evidence from a comprehensive meta-analysis.
Huang G; Wang P; Li T; Deng X
Clin Cardiol; 2019 Dec; 42(12):1232-1238. PubMed ID: 31701558
[TBL] [Abstract][Full Text] [Related]
25. Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis.
Berry CN; Lunven C; Lechaire I; Girardot C; O'Connor SE
Br J Pharmacol; 1998 Sep; 125(1):29-34. PubMed ID: 9776340
[TBL] [Abstract][Full Text] [Related]
26. Thrombogenesis with continuous blood flow in the inferior vena cava. A novel mouse model.
Diaz JA; Hawley AE; Alvarado CM; Berguer AM; Baker NK; Wrobleski SK; Wakefield TW; Lucchesi BR; Myers DD
Thromb Haemost; 2010 Aug; 104(2):366-75. PubMed ID: 20589322
[TBL] [Abstract][Full Text] [Related]
27. Failure to lyse venous thrombi because of elevated plasminogen activator Inhibitor 1 (PAI-1) and 4G polymorphism of its promotor genome (The PAI-1/4G Syndrome).
Bern MM; McCarthy N
Clin Appl Thromb Hemost; 2010 Oct; 16(5):574-8. PubMed ID: 20724304
[TBL] [Abstract][Full Text] [Related]
28. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
Bollen L; Peetermans M; Peeters M; Van Steen K; Hoylaerts MF; Declerck PJ; Verhamme P; Gils A
Thromb Res; 2014 Nov; 134(5):1097-102. PubMed ID: 25193405
[TBL] [Abstract][Full Text] [Related]
29. Combined Effect of MTHFR C677T and PAI-1 4G/5G Polymorphisms on the Risk of Venous Thromboembolism in Chinese Lung Cancer Patients.
Wang B; Xu P; Shu Q; Yan S; Xu H
Clin Appl Thromb Hemost; 2021; 27():10760296211031291. PubMed ID: 34325549
[TBL] [Abstract][Full Text] [Related]
30. Functional stability of plasminogen activator inhibitor-1.
Yasar Yildiz S; Kuru P; Toksoy Oner E; Agirbasli M
ScientificWorldJournal; 2014; 2014():858293. PubMed ID: 25386620
[TBL] [Abstract][Full Text] [Related]
31. Mucin 1 and venous thrombosis in tumor-bearing mice and patients with cancer.
Kawano T; Englisch C; Hisada Y; Paul D; Archibald S; Grover S; Pabinger I; Ay C; Mackman N
Thromb Res; 2024 May; 237():23-30. PubMed ID: 38547690
[TBL] [Abstract][Full Text] [Related]
32. AKT2 regulates endothelial-mediated coagulation homeostasis and promotes intrathrombotic recanalization and thrombus resolution in a mouse model of venous thrombosis.
Xie W; Zhang L; Luo W; Zhai Z; Wang C; Shen YH
J Thromb Thrombolysis; 2020 Jul; 50(1):98-111. PubMed ID: 32358666
[TBL] [Abstract][Full Text] [Related]
33. Prostaglandin-endoperoxide synthase-2 deletion affects the natural trafficking of Annexin A2 in monocytes and favours venous thrombosis in mice.
Amadio P; Tarantino E; Sandrini L; Tremoli E; Barbieri SS
Thromb Haemost; 2017 Jul; 117(8):1486-1497. PubMed ID: 28536720
[TBL] [Abstract][Full Text] [Related]
34. Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.
Dewyer NA; Sood V; Lynch EM; Luke CE; Upchurch GR; Wakefield TW; Kunkel S; Henke PK
J Surg Res; 2007 Oct; 142(2):357-63. PubMed ID: 17574586
[TBL] [Abstract][Full Text] [Related]
35. The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis.
Falkon L; Garí M; Borrell M; Fontcuberta J
Blood Coagul Fibrinolysis; 1992 Feb; 3(1):33-8. PubMed ID: 1623118
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen-induced aggregation of PANC-1 cells requires conversion to plasmin and is inhibited by endogenous plasminogen activator inhibitor-1.
Deshet N; Lupu-Meiri M; Espinoza I; Fili O; Shapira Y; Lupu R; Gershengorn MC; Oron Y
J Cell Physiol; 2008 Sep; 216(3):632-9. PubMed ID: 18366077
[TBL] [Abstract][Full Text] [Related]
37. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis.
Wang J; Wang C; Chen N; Shu C; Guo X; He Y; Zhou Y
Thromb Res; 2014 Dec; 134(6):1241-8. PubMed ID: 25450536
[TBL] [Abstract][Full Text] [Related]
38. Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults.
Ringelstein M; Jung A; Berger K; Stoll M; Madlener K; Klötzsch C; Schlachetzki F; Stolz E
J Neurol; 2012 Nov; 259(11):2287-92. PubMed ID: 22527222
[TBL] [Abstract][Full Text] [Related]
39. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1.
Eren M; Painter CA; Atkinson JB; Declerck PJ; Vaughan DE
Circulation; 2002 Jul; 106(4):491-6. PubMed ID: 12135951
[TBL] [Abstract][Full Text] [Related]
40. Plasminogen activator inhibitor-1 gene promoter 4G/5G polymorphism and risks of peripherally inserted central catheter-related venous thrombosis in patients with lung cancer: a prospective cohort study.
Feng Y; Fu Y; Xiang Q; Xie L; Yu C; Li J
Support Care Cancer; 2021 Nov; 29(11):6431-6439. PubMed ID: 33893843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
